Amgen Expands Inflammation Pipeline With Avidia Purchase
This article was originally published in The Pink Sheet Daily
$380 mil. deal for private company gives Amgen Phase I interleukin 6 inhibitor, novel protein development platform.
You may also be interested in...
Companies with large-molecule expertise increasingly are eyeing primary care markets, confident that improvements in safety and efficacy will make them competitive with oral standards of care.
The UK-based pharma’s corporate venture arm now has $400 million under management in an evergreen fund, with an expanded global focus that includes health care information technology.
Foraker advises competitors to “watch out” for new Amgen initiatives in Asia “in the coming months.”